Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SR9009 |
Synonyms | |
Therapy Description |
SR9009 is a synthetic agonist of REV-ERB nuclear receptors that may lead to suppression of tumorigenesis processes (PMID: 29320480, PMID: 32292508). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SR9009 | SR-9009|SR 9009 | SR9009 is a synthetic agonist of REV-ERB nuclear receptors that may lead to suppression of tumorigenesis processes (PMID: 29320480, PMID: 32292508). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS G12V | Advanced Solid Tumor | predicted - sensitive | SR9009 | Preclinical - Cell culture | Actionable | In a preclinical study, SR9009 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480). | 29320480 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|